(Q44064247)

29 November 2017

Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study (English)

1 reference

29 November 2017

0 references

1 reference

1 reference

Alfredo Halpern

1

1 reference

29 November 2017

Claudia Cozer Leite

2

1 reference

29 November 2017

Nathan Herszkowicz

3

1 reference

29 November 2017

Alfonso Barbato

4

1 reference

29 November 2017

Ana Paula Arruda Costa

5

1 reference

29 November 2017

1 May 2002

1 reference

Revista do Hospital das Clinicas

29 November 2017

1 reference

29 November 2017

57

1 reference

29 November 2017

3

1 reference

29 November 2017

98-102

1 reference

Relation of body fat distribution to metabolic complications of obesity.

29 November 2017

1 reference

https://api.crossref.org/works/10.1590%2FS0041-87812002000300003

Sibutramine produces dose-related weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0041-87812002000300003

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0041-87812002000300003

Cardiovascular adaptation to obesity and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0041-87812002000300003

Valvular heart disease associated with fenfluramine-phentermine

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0041-87812002000300003

Absence of cardiac valve dysfunction in obese patients treated with sibutramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0041-87812002000300003

The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0041-87812002000300003

10.1590/S0041-87812002000300003

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference